Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Orthopedic Research and Education Foundation | OTHER |
Not provided
Not provided
Not provided
Not provided
The purpose of our study is to examine the effect of platelet-rich-plasma (PRP) injection on the short-term resolution of post-injury inflammation (biomarkers) and improvement in joint function in patients with acute ACL injury. This RCT has been powered based on the questionnaire KOOS Jr. but it is considered a 'pilot study' in terms of the lab analysis proposed.
Anterior cruciate ligament (ACL) injury is one of the most common clinical problems among active individuals, with over 250,000 ACL reconstructions (ACLR) per year in the United States. Surgical reconstruction of the ACL is typically required in individuals who wish to return to an active lifestyle due to the presence of knee instability. The results of ACLR are predictably good as far as the ability to re-establish knee stability and to allow return to cutting and pivoting activities. However, there is a lack of effective interventions that can successfully delay or prevent the progressive degenerative changes that are known to occur following injury and that will ultimately lead to post-traumatic osteoarthritis (PTOA). PTOA accounts for nearly 12% of all cases of symptomatic OA, or approximately 5.6 million cases of lower extremity OA in the United States, carrying a cost of over $11.8 billion annually. As injury rates rise and PTOA becomes more prevalent, the associated socioeconomic burden is a significant concern since these injuries have a particularly high incidence in young adults. Many different factors likely contribute to the development of PTOA following ACLR, including the inflammatory response that occurs following injury, altered knee kinematics that can persist despite "successful" ACLR, and persistent deficits in strength of the muscles around the knee. It is well-accepted that the accumulation of inflammatory mediators and matrix degrading proteases that occurs following joint injury likely plays an important role in the initiation of the pathological process leading to PTOA. Work in animal models shows that synovial inflammation plays a central role in the development of PTOA, and studies in patients undergoing ACLR uncovered synovial fluid biomarkers with prognostic value and showed that treatment with anti-inflammatory agents modulated biomarkers of cartilage degeneration. Our preliminary RNA-seq in synovial biopsies from patients undergoing arthroscopic ACLR revealed time-dependent changes in the inflammatory gene expression profile of these tissues, further suggesting that preventative therapies that dampen inflammation early after injury and before surgery may contribute to prevent the onset of PTOA. Abnormalities in the infrapatellar fat pad (IFP) are also associated with higher inflammatory synovial fluid cytokine profile following ACL tear, highlighting the contribution of the IFP-synovial compartment to the inflammatory burden of the knee. In addition to the inflammatory response that occurs following injury, inflammation also occurs following surgery. This "double hit" may play an important role in the development of PTOA, suggesting that methods to ameliorate the inflammatory process following joint injury could represent an effective therapeutic strategy.
The current standard methods available to clinicians to treat joint inflammation include oral non-steroidal anti-inflammatory (NSAID) medications and corticosteroid injection. However, clinicians have begun to use "orthobiologics" more frequently due to their potential to diminish inflammatory and catabolic mediators while also promoting repair, and because its autologous and minimally manipulated nature is not subjected to pre-market regulatory clearance from the Food and Drug Administration. Platelet rich plasma (PRP) is a non-surgical therapy increasingly used as an alternative to NSAIDs. PRP contains and releases a wide array of bioactive molecules it has been used to treat bone, tendon, and ligament injuries, and has emerged as a potential treatment for knee osteoarthritis (OA). The currently available studies comparing intra-articular PRP injections to other means of non-surgical intervention for knee OA report promising results with the use of PRP. These data suggest that positive clinical results in OA patients are mainly related to the immune modulatory effects of PRP, dampening the intra-articular inflammatory responses.
However, the role of PRP in the treatment of knee OA remains inconclusive, largely due to inconsistencies and high variability in PRP preparations, and the limited information about the relevant components in PRP that impact clinical responses. Factors including age, sex, medical comorbidities, and genetic profile may affect the composition and biologic activity of PRP samples derived from different individuals. In addition to inter-individual variations, there is currently very little data to define how the composition and biologic activity of PRP relates to the clinical outcomes. Our recent pilot data suggests that, indeed, there are changes in composition and PRP bioactivity that may be associated with variable clinical outcomes in patients with established knee OA receiving intra-articular PRP injections. However, larger clinical trials are still required to better define these changes and to establish truly mechanistic and functional correlations. Thus, a large knowledge gap remains in our understanding of the biologically active components of PRP. Furthermore, the limited data available related to PRP and knee OA addresses treatment of established OA. There is no information available about the potential of PRP for prevention of the pathological cascade leading to PTOA.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control Arm | Placebo Comparator | The control arm will receive a pre-op placebo injection of saline, and ACLR surgery with intra-op placebo injection |
|
| Investigational Arm | Experimental | The investigational arm will receive a pre-op PRP injection, and ACLR surgery with PRP injection |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| platelet rich plasma (PRP) injection | Procedure | We aim to evaluate early catabolic and inflammatory changes in knee joints in patients receiving PRP injections following ACL injury, as these patients are at higher risk of developing PTOA. We also aim to establish correlations between markers of biologic activity of PRP and clinical outcomes (including both patient-reported outcomes and clinical functional outcomes), with emphasis on cellular and molecular inflammatory parameters modulated by PRP. |
| Measure | Description | Time Frame |
|---|---|---|
| Platelet count (Thousand/uL) | Platelet count (Thousand/uL) will be measured by completing a complete blood count on patient's blood sample. | Baseline |
| Platelet count (Thousand/uL) | Platelet count (Thousand/uL) will be measured by completing a complete blood count on patient's blood sample. | during the procedure |
| Knee Injury and Osteoarthritis Outcome (KOOS-JR) | This survey asks about how the patient feels about their knee. The information helps keep track of how the patient feels about their knee and how well they are able to do their usual activities. There is no unique measurements. Answer options per question regarding stiffness, pain, function, daily and living are: None, Mild, Moderate, Severe, and Extreme | Baseline |
| Knee Injury and Osteoarthritis Outcome (KOOS-JR) | This survey asks about how the patient feels about their knee. The information helps keep track of how the patient feels about their knee and how well they are able to do their usual activities. There is no unique measurements. Answer options per question regarding stiffness, pain, function, daily and living are: None, Mild, Moderate, Severe, and Extreme | during the procedure |
| Knee Injury and Osteoarthritis Outcome (KOOS-JR) | This survey asks about how the patient feels about their knee. The information helps keep track of how the patient feels about their knee and how well they are able to do their usual activities. There is no unique measurements. Answer options per question regarding stiffness, pain, function, daily and living are: None, Mild, Moderate, Severe, and Extreme | 2 weeks post-op |
| Measure | Description | Time Frame |
|---|---|---|
| Knee stability | Using the KT1000 arthrometer | 6 months post-surgery |
| Knee stability | Using the KT1000 arthrometer | 12 months post-surgery |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jessica Andres-Bergos, PhD | Contact | (917) 260-4694 | andresbergosj@hss.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital for Special Surgery | Recruiting | New York | New York | 10021 | United States |
Not provided
| Label | URL |
|---|---|
| Related information | View source |
| Related information | View source |
| Related information |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000070598 | Anterior Cruciate Ligament Injuries |
| ID | Term |
|---|---|
| D007718 | Knee Injuries |
| D007869 | Leg Injuries |
| D014947 | Wounds and Injuries |
Not provided
Not provided
| ID | Term |
|---|---|
| D007267 | Injections |
| ID | Term |
|---|---|
| D004333 | Drug Administration Routes |
| D004358 | Drug Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
PRP is considered a biologic.
We designed a double-blinded randomized controlled clinical trial with two arms:
Not provided
Not provided
Not provided
|
|
| placebo saline injection | Procedure | Patients randomized into the control arm will receive the placebo or saline injection |
|
| Knee Injury and Osteoarthritis Outcome (KOOS-JR) |
This survey asks about how the patient feels about their knee. The information helps keep track of how the patient feels about their knee and how well they are able to do their usual activities. There is no unique measurements. Answer options per question regarding stiffness, pain, function, daily and living are: None, Mild, Moderate, Severe, and Extreme |
| 6 weeks post-op |
| Knee Injury and Osteoarthritis Outcome (KOOS-JR) | This survey asks about how the patient feels about their knee. The information helps keep track of how the patient feels about their knee and how well they are able to do their usual activities. There is no unique measurements. Answer options per question regarding stiffness, pain, function, daily and living are: None, Mild, Moderate, Severe, and Extreme | 6 months post-op |
| Knee Injury and Osteoarthritis Outcome (KOOS-JR) | This survey asks about how the patient feels about their knee. The information helps keep track of how the patient feels about their knee and how well they are able to do their usual activities. There is no unique measurements. Answer options per question regarding stiffness, pain, function, daily and living are: None, Mild, Moderate, Severe, and Extreme | 12 months post-op |
| Knee Injury and Osteoarthritis Outcome (KOOS-JR) | This survey asks about how the patient feels about their knee. The information helps keep track of how the patient feels about their knee and how well they are able to do their usual activities. There is no unique measurements. Answer options per question regarding stiffness, pain, function, daily and living are: None, Mild, Moderate, Severe, and Extreme | 24 months post-op |
| Numeric Pain Rating Scale (NPRS) | This survey asks about the patient's pain levels. Patient will be reporting a score on a scale from 0 to 10, with 0 being "No Pain" and 10 being "Worst Pain Imaginable" | Baseline |
| Numeric Pain Rating Scale (NPRS) | This survey asks about the patient's pain levels. Patient will be reporting a score on a scale from 0 to 10, with 0 being "No Pain" and 10 being "Worst Pain Imaginable" | during the procedure |
| Numeric Pain Rating Scale (NPRS) | This survey asks about the patient's pain levels. Patient will be reporting a score on a scale from 0 to 10, with 0 being "No Pain" and 10 being "Worst Pain Imaginable" | 6 weeks post-op |
| Numeric Pain Rating Scale (NPRS) | This survey asks about the patient's pain levels. Patient will be reporting a score on a scale from 0 to 10, with 0 being "No Pain" and 10 being "Worst Pain Imaginable" | 6 months post-op |
| Numeric Pain Rating Scale (NPRS) | This survey asks about the patient's pain levels. Patient will be reporting a score on a scale from 0 to 10, with 0 being "No Pain" and 10 being "Worst Pain Imaginable" | 12 months post-op |
| Numeric Pain Rating Scale (NPRS) | This survey asks about the patient's pain levels. Patient will be reporting a score on a scale from 0 to 10, with 0 being "No Pain" and 10 being "Worst Pain Imaginable" | 24 months post-op |
| Patient-Reported Outcomes Measurement Information System 10 (PROMIS-10) | This survey asks about the patient's overall health and quality of life. Patient will be reporting on a Likert Scale formatted in the following manner for questions 1-6: 5 = "Excellent", 4 = "Very good", 3 = "Good", 2 = "Fair", 1 = "Poor" Patient will be reporting on a Likert Scale formatted in the following manner for question 7: 5 = "Completely", 4 = "Mostly", 3 = "Moderately", 2 = "A little", 1 = "Not at all" Patient will be reporting on a Likert Scale formatted in the following manner for question 8: 1= "Never", 2 = "Rarely", 3 = "Sometimes", 4 = "Often", 5 = "Always" Patient will be reporting on a Likert Scale formatted in the following manner for question 9: 1= "None", 2 = "Mild", 3 = "Moderate", 4 = "Severe", 5 = "Very Severe" For question 10: Patient will be reporting a score on a scale from 0 to 10, with 0 being "No Pain" and 10 being "Worst Pain Imaginable" | Baseline |
| Patient-Reported Outcomes Measurement Information System 10 (PROMIS-10) | This survey asks about the patient's overall health and quality of life. Patient will be reporting on a Likert Scale formatted in the following manner for questions 1-6: 5 = "Excellent", 4 = "Very good", 3 = "Good", 2 = "Fair", 1 = "Poor" Patient will be reporting on a Likert Scale formatted in the following manner for question 7: 5 = "Completely", 4 = "Mostly", 3 = "Moderately", 2 = "A little", 1 = "Not at all" Patient will be reporting on a Likert Scale formatted in the following manner for question 8: 1= "Never", 2 = "Rarely", 3 = "Sometimes", 4 = "Often", 5 = "Always" Patient will be reporting on a Likert Scale formatted in the following manner for question 9: 1= "None", 2 = "Mild", 3 = "Moderate", 4 = "Severe", 5 = "Very Severe" For question 10: Patient will be reporting a score on a scale from 0 to 10, with 0 being "No Pain" and 10 being "Worst Pain Imaginable" | during the procedure |
| Patient-Reported Outcomes Measurement Information System 10 (PROMIS-10) | This survey asks about the patient's overall health and quality of life. Patient will be reporting on a Likert Scale formatted in the following manner for questions 1-6: 5 = "Excellent", 4 = "Very good", 3 = "Good", 2 = "Fair", 1 = "Poor" Patient will be reporting on a Likert Scale formatted in the following manner for question 7: 5 = "Completely", 4 = "Mostly", 3 = "Moderately", 2 = "A little", 1 = "Not at all" Patient will be reporting on a Likert Scale formatted in the following manner for question 8: 1= "Never", 2 = "Rarely", 3 = "Sometimes", 4 = "Often", 5 = "Always" Patient will be reporting on a Likert Scale formatted in the following manner for question 9: 1= "None", 2 = "Mild", 3 = "Moderate", 4 = "Severe", 5 = "Very Severe" For question 10: Patient will be reporting a score on a scale from 0 to 10, with 0 being "No Pain" and 10 being "Worst Pain Imaginable" | 2 weeks post-op |
| Patient-Reported Outcomes Measurement Information System 10 (PROMIS-10) | This survey asks about the patient's overall health and quality of life. Patient will be reporting on a Likert Scale formatted in the following manner for questions 1-6: 5 = "Excellent", 4 = "Very good", 3 = "Good", 2 = "Fair", 1 = "Poor" Patient will be reporting on a Likert Scale formatted in the following manner for question 7: 5 = "Completely", 4 = "Mostly", 3 = "Moderately", 2 = "A little", 1 = "Not at all" Patient will be reporting on a Likert Scale formatted in the following manner for question 8: 1= "Never", 2 = "Rarely", 3 = "Sometimes", 4 = "Often", 5 = "Always" Patient will be reporting on a Likert Scale formatted in the following manner for question 9: 1= "None", 2 = "Mild", 3 = "Moderate", 4 = "Severe", 5 = "Very Severe" For question 10: Patient will be reporting a score on a scale from 0 to 10, with 0 being "No Pain" and 10 being "Worst Pain Imaginable" | 6 weeks post-op |
| Patient-Reported Outcomes Measurement Information System 10 (PROMIS-10) | This survey asks about the patient's overall health and quality of life. Patient will be reporting on a Likert Scale formatted in the following manner for questions 1-6: 5 = "Excellent", 4 = "Very good", 3 = "Good", 2 = "Fair", 1 = "Poor" Patient will be reporting on a Likert Scale formatted in the following manner for question 7: 5 = "Completely", 4 = "Mostly", 3 = "Moderately", 2 = "A little", 1 = "Not at all" Patient will be reporting on a Likert Scale formatted in the following manner for question 8: 1= "Never", 2 = "Rarely", 3 = "Sometimes", 4 = "Often", 5 = "Always" Patient will be reporting on a Likert Scale formatted in the following manner for question 9: 1= "None", 2 = "Mild", 3 = "Moderate", 4 = "Severe", 5 = "Very Severe" For question 10: Patient will be reporting a score on a scale from 0 to 10, with 0 being "No Pain" and 10 being "Worst Pain Imaginable" | 6 months post-op |
| Patient-Reported Outcomes Measurement Information System 10 (PROMIS-10) | This survey asks about the patient's overall health and quality of life. Patient will be reporting on a Likert Scale formatted in the following manner for questions 1-6: 5 = "Excellent", 4 = "Very good", 3 = "Good", 2 = "Fair", 1 = "Poor" Patient will be reporting on a Likert Scale formatted in the following manner for question 7: 5 = "Completely", 4 = "Mostly", 3 = "Moderately", 2 = "A little", 1 = "Not at all" Patient will be reporting on a Likert Scale formatted in the following manner for question 8: 1= "Never", 2 = "Rarely", 3 = "Sometimes", 4 = "Often", 5 = "Always" Patient will be reporting on a Likert Scale formatted in the following manner for question 9: 1= "None", 2 = "Mild", 3 = "Moderate", 4 = "Severe", 5 = "Very Severe" For question 10: Patient will be reporting a score on a scale from 0 to 10, with 0 being "No Pain" and 10 being "Worst Pain Imaginable" | 12 months post-op |
| Patient-Reported Outcomes Measurement Information System 10 (PROMIS-10) | This survey asks about the patient's overall health and quality of life. Patient will be reporting on a Likert Scale formatted in the following manner for questions 1-6: 5 = "Excellent", 4 = "Very good", 3 = "Good", 2 = "Fair", 1 = "Poor" Patient will be reporting on a Likert Scale formatted in the following manner for question 7: 5 = "Completely", 4 = "Mostly", 3 = "Moderately", 2 = "A little", 1 = "Not at all" Patient will be reporting on a Likert Scale formatted in the following manner for question 8: 1= "Never", 2 = "Rarely", 3 = "Sometimes", 4 = "Often", 5 = "Always" Patient will be reporting on a Likert Scale formatted in the following manner for question 9: 1= "None", 2 = "Mild", 3 = "Moderate", 4 = "Severe", 5 = "Very Severe" For question 10: Patient will be reporting a score on a scale from 0 to 10, with 0 being "No Pain" and 10 being "Worst Pain Imaginable" | 24 months post-op |
| Single Assessment Numeric Evaluation (SANE) | This survey asks how the patient feels about their knee. Patient will be reporting a percentage from 0% to 100%, with 100% being normal. | Baseline |
| Single Assessment Numeric Evaluation (SANE) | This survey asks how the patient feels about their knee. Patient will be reporting a percentage from 0% to 100%, with 100% being normal. | during the procedure |
| Single Assessment Numeric Evaluation (SANE) | This survey asks how the patient feels about their knee. Patient will be reporting a percentage from 0% to 100%, with 100% being normal. | 2 weeks post-op |
| Single Assessment Numeric Evaluation (SANE) | This survey asks how the patient feels about their knee. Patient will be reporting a percentage from 0% to 100%, with 100% being normal. | 6 weeks post-op |
| Single Assessment Numeric Evaluation (SANE) | This survey asks how the patient feels about their knee. Patient will be reporting a percentage from 0% to 100%, with 100% being normal. | 6 months post-op |
| Single Assessment Numeric Evaluation (SANE) | This survey asks how the patient feels about their knee. Patient will be reporting a percentage from 0% to 100%, with 100% being normal. | 12 months post-op |
| Single Assessment Numeric Evaluation (SANE) | This survey asks how the patient feels about their knee. Patient will be reporting a percentage from 0% to 100%, with 100% being normal. | 24 months post-op |
| Knee stability | Using the KT1000 arthrometer | 24 months post-surgery |
| Knee strength | Using the Cybex test | 6 months post-surgery |
| Knee strength | Using the Cybex test | 12 months post-surgery |
| Knee strength | Using the Cybex test | 24 months post-surgery |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |
| Related information | View source |